Levothyroxine dose for checkpoint inhibitor toxicity may be too highNovember 4, 2019MelanomaLung CancerPatient & Survivor CareImmunotherapy
Immune checkpoint inhibition in SCLC: Modest outcomes, many questionsNovember 4, 2019Lung CancerImmuno-oncology
Patients have good recall on lung cancer screening scan benefits, not risksOctober 26, 2019Lung Cancer
Stereotactic body radiation therapy safe, effective for moderately central NSCLCOctober 24, 2019Lung Cancer
Immunotherapy duo extends survival in first line for advanced NSCLCSeptember 29, 2019Lung CancerLung Cancer
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkersSeptember 29, 2019Lung Cancer
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroupsSeptember 27, 2019Lung Cancer
OS benefit with pembrolizumab endures long-term in advanced NSCLCSeptember 24, 2019Lung CancerImmuno-oncology
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapySeptember 23, 2019Lung Cancer
